FDA Gives Clearance to In Vivo Gene-Editing Therapy for AATD The FDA has approved the Investigational New Drug application for YOLT-202, an in vivo gene-editing therapy for AATD.

The @fda.gov has approved the Investigational New Drug (#IND) application for YOLT-202, an in vivo gene-editing therapy for alpha-1 antitrypsin deficiency (#AATD), according to a recent press release.

Read more: https://bit.ly/4draiFV

#RareDisease #YOLT202 #GeneEditingTherapy #Alpha1